Mindwalk identified TDP-43 antibodies that selectively target abnormal protein clumps linked to ALS and other diseases.

A study suggests overactive VCP may contribute to ALS nerve damage by disrupting nuclear pore proteins in genetic ALS.

University of Utah researchers at the Pulst-Scoles Laboratory have discovered that reducing levels of the STAUFEN-1 protein ...

Some evidence reports natural medications, such as Wugongtang and Dihuangyinzi, may help slow the progression of ALS or Lou Gehrig’s disease. However, they cannot cure it. Amyotrophic lateral ...

The MarketWatch News Department was not involved in the creation of this content. The First Synaptic Regenerative Drug, SPG302, Led to Slowed Disease Progression in ALS Patients LOS ANGELES, Nov. 4, ...

Currently, the MyoRegulator® device is under investigation as a non-invasive treatment for ALS in a second and larger clinical trial, the CALM ( C ontrolling A myotrophic L ateral Sclerosis M otor ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO™ ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Neuvivo, a late-clinical stage biopharmaceutical company, today announced it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) ...

The Food and Drug Administration (FDA) has not approved stem cell therapy for amyotrophic lateral sclerosis (ALS). However, people could participate in clinical trials involving this ALS treatment.

The Food and Drug Administration on Friday approved Radicava — a new treatment for amyotrophic lateral sclerosis, or Lou Gehrig’s disease. Here are five things to know. 1. Radicava marks the first FDA ...

In May 2022, The US FDA authorized the use of RADICAVA ORS (edaravone) in an oral formulation for the treatment of ALS.